242 related articles for article (PubMed ID: 16104904)
1. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
Sakai I; Harada K; Hara I; Eto H; Miyake H
BJU Int; 2005 Sep; 96(4):528-32. PubMed ID: 16104904
[TBL] [Abstract][Full Text] [Related]
2. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones.
Sakai I; Harada K; Kurahashi T; Yamanaka K; Hara I; Miyake H
Int J Urol; 2006 Apr; 13(4):368-72. PubMed ID: 16734852
[TBL] [Abstract][Full Text] [Related]
3. Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy.
Chun FK; Briganti A; Jeldres C; Erbersdobler A; Schlomm T; Steuber T; Gallina A; Walz J; Perrotte P; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2007 Apr; 51(4):949-55; discussion 955. PubMed ID: 16904818
[TBL] [Abstract][Full Text] [Related]
4. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones.
Augustin H; Erbersdobler A; Graefen M; Fernandez S; Palisaar J; Huland H; Hammerer P
Prostate; 2003 Apr; 55(1):48-54. PubMed ID: 12640660
[TBL] [Abstract][Full Text] [Related]
5. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
6. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
[TBL] [Abstract][Full Text] [Related]
7. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
Steuber T; Karakiewicz PI; Augustin H; Erbersdobler A; Lange I; Haese A; Chun KH; Walz J; Graefen M; Huland H
J Urol; 2005 Mar; 173(3):737-41. PubMed ID: 15711259
[TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
O'Neil LM; Walsh S; Cohen RJ; Lee S
BJU Int; 2015 Oct; 116 Suppl 3():42-8. PubMed ID: 26218868
[TBL] [Abstract][Full Text] [Related]
9. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
Erbersdobler A; Huhle S; Palisaar J; Graefen M; Hammerer P; Noldus J; Huland H
Prostate Cancer Prostatic Dis; 2002; 5(4):279-84. PubMed ID: 12627212
[TBL] [Abstract][Full Text] [Related]
10. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
11. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate.
Erbersdobler A; Hammerer P; Huland H; Henke RP
J Urol; 1997 Oct; 158(4):1594-8. PubMed ID: 9302180
[TBL] [Abstract][Full Text] [Related]
12. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour.
Shannon BA; McNeal JE; Cohen RJ
Pathology; 2003 Dec; 35(6):467-71. PubMed ID: 14660095
[TBL] [Abstract][Full Text] [Related]
13. Predicting CAP in patients with intermediate PSA using modified PSA indices.
Zisman A; Leibovici D; Kleinmann J; Siegel YI; Lindner A
Can J Urol; 2000 Dec; 7(6):1144-8. PubMed ID: 11151095
[TBL] [Abstract][Full Text] [Related]
14. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
15. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
[TBL] [Abstract][Full Text] [Related]
16. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
17. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology.
Bouyé S; Potiron E; Puech P; Leroy X; Lemaitre L; Villers A
Prostate; 2009 Jan; 69(1):105-13. PubMed ID: 18850578
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
19. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
